Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RGS12 | O14924 | 3/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144263 | 0.88 | EGFR (0.78) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10186359 | 0.86 | EGFR (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8485552 | 0.86 | EGFR (0.75) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29457559 | 0.83 | EGFR (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3459584 | 0.83 | EGFR (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL12617223 | 0.83 | EGFR (0.70) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL31618898 | 0.79 | ALDH1A1 (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10144550 | 0.79 | ALDH1A1 (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8609619 | 0.79 | EGFR (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| Tyrphostin 23 SCHEMBL241922 | 0.78 | EGFR (1.00) | EGFRMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577832-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | Indivumed GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| WO-2024042077-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | INDIVUMED GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-2516626-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | JANSSEN BIOTECH INC (US) | 2017-05-10 | — | — | EP | claimed |
| US-9133439-B2 | Differentiation of human embryonic stem cells | JANSSEN BIOTECH, INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2516626-A2 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | Janssen Biotech, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| CN-102712902-A | Differentiation of human embryonic stem cells | CENTOCOR ORTHO BIOTECH INC | 2012-10-03 | — | — | CN | claimed |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20080286670-A1 | Photoconductors containing charge transport chelating components | XEROX CORPORATION | 2008-11-20 | — | — | US | claimed |
| WO-2007106432-A2 | EGF RECEPTOR PHOSPHORYLATION STATUS FOR DISEASE TREATMENT | GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-7052692-B1 | Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 2006-05-30 | — | — | US | claimed |
| EP-1156775-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | claimed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | claimed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | claimed |
| EP-0403238-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-12-19 | — | — | EP | claimed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | EGFR 3/4885MEN1 2801/4885KMT2A 1292/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | EGFR 3/4885MEN1 2296/4885KMT2A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.